Detalhe da pesquisa
1.
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Int J Cancer
; 154(6): 1043-1056, 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37994647
2.
Association between treatment-emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in the REFLECT study.
Cancer
; 130(8): 1281-1291, 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38261521
3.
Merits and boundaries of the BCLC staging and treatment algorithm: Learning from the past to improve the future with a novel proposal.
J Hepatol
; 80(4): 661-669, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38266658
4.
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours.
J Hepatol
; 80(3): 431-442, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37972660
5.
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Lancet
; 402(10415): 1835-1847, 2023 11 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37871608
6.
Activation of nucleotide-binding oligomerization domain 2 by muramyl dipeptide negatively regulates Toll-like receptor 9-mediated colonic inflammation through the induction of deubiquitinating enzyme A expression.
Int Immunol
; 35(2): 79-94, 2023 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36171063
7.
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
Liver Int
; 44(1): 113-124, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37789669
8.
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab.
Liver Int
; 44(5): 1108-1125, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38517286
9.
Current Trends and Advancements in the Management of Hepatocellular Carcinoma.
Dig Dis
; 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38599204
10.
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study.
Hepatol Res
; 54(4): 382-391, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37983642
11.
Crosstalk between NOD2 and TLR2 suppresses the development of TLR2-mediated experimental colitis.
J Clin Biochem Nutr
; 74(2): 146-153, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38510686
12.
Cytokine and chemokine profiles in ulcerative colitis relapse after coronavirus disease 2019 vaccination.
J Clin Biochem Nutr
; 74(2): 127-135, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38510687
13.
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 24(12): 1399-1410, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38039993
14.
Treatment of portal hypertension in patients with HCC in the era of Baveno VII.
J Hepatol
; 78(3): 658-662, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36460163
15.
Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.
J Hepatol
; 78(1): 133-141, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36341767
16.
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
N Engl J Med
; 382(20): 1894-1905, 2020 05 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32402160
17.
Breakthroughs in Hepatocellular Carcinoma Therapies.
Clin Gastroenterol Hepatol
; 21(8): 2135-2149, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36813012
18.
Oral administration of ovalbumin protects mice from concanavalin A-induced hepatitis through suppression of interferon-gamma responses.
Biochem Biophys Res Commun
; 674: 117-123, 2023 09 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37419032
19.
Leucine-rich repeat kinase 2 promotes the development of experimental severe acute pancreatitis.
Clin Exp Immunol
; 214(2): 182-196, 2023 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37847786
20.
Activation of the aryl hydrocarbon receptor inhibits the development of experimental autoimmune pancreatitis through IL-22-mediated signaling pathways.
Clin Exp Immunol
; 2023 May 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37166987